sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. recently released its disclosure in accordance with the Irish Takeover Panel's rules concerning its stake in Avadel Pharmaceuticals plc. As of January 7, 2026, Vanguard owns and controls 5,865,407 US$0.01 ordinary shares of Avadel, representing a 6.02% interest. This information aligns with the parameters set by the Irish Takeover Panel Act, 1997.
In recent transactions, Vanguard purchased 2,030 shares and sold 66 shares at a price of 21.50 USD each. No new cash-settled or stock-settled derivative positions, nor any other relevant securities transactions, were reported.
The company confirmed absence of any indemnity or option arrangements, agreements, or understandings related to the securities or derivatives of Avadel Pharmaceuticals.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.